Research ArticleResearchMedication SafetyQuality Improvement

Conservative oxygen did not improve 180-day recovery after cardiac arrest

The New England journal of medicine (PubMed)Aug 6, 2026

AI-summarized from the linked source. Educational brief, not medical advice.

Brief summary

In a 53-ICU randomized trial of 1,840 unresponsive adults receiving mechanical ventilation after cardiac arrest, conservative oxygen therapy did not increase survival with a favorable functional outcome at 180 days compared with a more liberal strategy.

What NurseJet pulled from the source

The conservative strategy used an upper oxygen-saturation alarm of 95% and allowed the inspired oxygen fraction to fall to 0.21, while both groups shared a 90% lower saturation limit. Favorable functional outcomes occurred in 38.2% and 39.7% of analyzed patients, respectively, providing no evidence that the conservative strategy improved the primary outcome.

Why this matters for nurses

Critical-care nurses titrate oxygen, respond to saturation alarms, and monitor neurological and respiratory status after cardiac arrest. This large trial helps separate avoidance of unnecessary oxygen exposure from an assumption that a tighter upper saturation target improves longer-term recovery.

Bedside takeaway

Use the ordered post-arrest oxygen range and titration plan; this trial did not show better recovery from the tested conservative strategy.

How This Applies in Practice

Use this when: Caring for an unresponsive adult receiving mechanical ventilation after cardiac-arrest resuscitation.

On your shift

Verify the prescribed lower and upper oxygen-saturation limits, inspired-oxygen titration instructions, blood-gas plan, and neurological-monitoring schedule at handoff.
Trend saturation, inspired oxygen, ventilator parameters, hemodynamics, and neurological findings together rather than responding to one value in isolation.
Escalate sustained readings outside the ordered range, rising oxygen needs, ventilator concerns, or acute neurological or hemodynamic deterioration.

Keep in mind: The tested strategies do not define the right target for every post-arrest patient. Follow the critical-care protocol, facility policy, and provider orders.

Key takeaways

The multicenter trial enrolled 1,840 mechanically ventilated adults who remained unresponsive after cardiac-arrest resuscitation.
Survival with a favorable 180-day functional outcome was 38.2% with conservative oxygen and 39.7% with liberal oxygen.
The relative risk was 0.97 with a 95% confidence interval from 0.87 to 1.09.
The trial compared specific oxygen protocols and does not support changing an individual patient's ordered targets without the treating team's direction.

Practice implications

Confirm the ordered post-arrest saturation range and oxygen-titration plan at handoff, trend oxygenation with ventilation and neurological findings, and document changes in support. Escalate hypoxemia, ventilator problems, or acute neurological or hemodynamic change through the unit pathway.

Limitations & cautions

The trial studied unresponsive, mechanically ventilated adults in ICUs in Australia, New Zealand, and Ireland using two specific oxygen protocols. It does not establish the best target for patients outside those criteria, and the primary-outcome denominators were lower than the numbers assigned to each group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations

Exact source links

Open source

Public citations are filtered to exact credible source pages. Homepage-only or invalid links stay in admin review and are not shown here.

The New England journal of medicine (PubMed)

The New England journal of medicine (PubMed). Conservative Oxygen for Unresponsive Patients after Cardiac Arrest.

Open original source

https://pubmed.ncbi.nlm.nih.gov/42267831/

Professional education only

This summary does not replace clinical judgment, facility policy, provider orders, or official guidelines. Verify practice changes against the original source and local protocol.

Related briefs

More updates for this clinical area

Back to Discover

Pediatric emergency care (PubMed)Sep 7, 2026Research Article

A double-blind randomized trial found no reduction in vomiting or faster oral tolerance with intravenous pantoprazole versus placebo in children with acute gastroenteritis and persistent vomiting after ondansetron.

Peds EmergencyAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 100 children. Vomiting episodes and oral tolerance at 6 and 12 hours did not differ significantly, while median hospital stay was 2 days with pantoprazole and 1 day with placebo.

Key takeaways

The median participant age was 14 months, and 67% of participants were male.
Oral tolerance at 12 hours was 86% in both groups.
The longer stay associated with pantoprazole requires cautious interpretation because this was a single-center trial.

Why this matters on shift

The trial does not support empiric intravenous proton-pump inhibition for persistent vomiting in pediatric acute gastroenteritis after ondansetron.

Bedside takeaway

Clarify the indication for empiric acid suppression and keep hydration and oral-tolerance assessment central to care.

Nursing implications

Prioritize the ordered hydration and oral-tolerance plan, document ongoing emesis, and clarify the indication before administering empiric acid suppression.

Limitations & cautions

Abstract-only summary. This was a single-center study of 100 children in Tehran, and the abstract does not describe adverse events or explain why hospitalization was longer in the pantoprazole group.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Pediatric emergency care (PubMed). Effect of Intravenous Pantoprazole on Clinical Outcomes in Pediatric Acute Gastroenteritis: A Placebo-Controlled RCT.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

European heart journal (PubMed)Sep 6, 2026Research Article

In the pragmatic TARGET-D randomized trial, vitamin D dosing titrated to a serum target did not significantly reduce the composite of death, recurrent myocardial infarction, heart-failure hospitalization, or stroke after myocardial infarction.

Telemetry Med-SurgAI summaryReview source

Research ArticleResearchMedication SafetyPatient EducationAI summary · original source linked below

Among 630 participants followed for an average of 4.2 years, major cardiovascular events occurred in 15.7% with targeted vitamin D management and 18.4% with usual care (hazard ratio 0.85, 95% CI 0.58 to 1.24; P=0.40).

Key takeaways

At baseline, 87% of participants had a 25-hydroxyvitamin D level of 40 ng/mL or lower.
The primary composite outcome and the individual outcomes of death, heart-failure hospitalization, and stroke were not significantly different.
A lower recurrent-MI rate was a secondary finding and should not override the nonsignificant primary result.

Why this matters on shift

The trial cautions against presenting targeted vitamin D supplementation as a proven strategy for reducing major cardiovascular events after myocardial infarction.

Bedside takeaway

Present vitamin D as prescribed supplementation, not as a replacement for established post-MI secondary prevention.

Nursing implications

Reinforce the prescribed secondary-prevention plan and avoid implying that vitamin D replaces therapies with established post-MI benefit.

Limitations & cautions

Abstract-only summary. The trial included 630 participants, 78.1% were men, the primary confidence interval included benefit and no benefit, and individual secondary outcomes were not the primary endpoint.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

European heart journal (PubMed). Targeted vitamin D supplementation and major adverse cardiovascular events after myocardial infarction: the TARGET-D trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

Journal of neurosurgical anesthesiology (PubMed)Sep 4, 2026Research Article

A five-center randomized trial found similar rescue-opioid use and moderate-to-severe PACU pain with dexmedetomidine-based opioid-sparing analgesia and fentanyl-based analgesia during elective craniotomy for brain tumors.

Emergency ICUAI summaryReview source

Research ArticleResearchMedication SafetyAI summary · original source linked below

The trial randomized 500 adults. Moderate-to-severe PACU pain occurred in 145 of 242 assessed participants in the fentanyl group and 138 of 233 in the dexmedetomidine group, with no significant difference.

Key takeaways

Intraoperative rescue fentanyl use did not differ significantly between groups.
Hypotension was more common with dexmedetomidine, while postoperative shivering was less common.
Other in-hospital outcomes were similar between the two regimens.

Why this matters on shift

An opioid-sparing label did not translate into better early pain control in this trial, and the differing hypotension and shivering profiles remain relevant during perioperative handoff and recovery monitoring.

Bedside takeaway

Monitor pain, hemodynamics, sedation, and shivering in relation to the analgesic regimen and local protocol.

Nursing implications

During PACU and postoperative handoff, monitor pain, hemodynamics, sedation, and shivering according to the administered regimen and local protocol.

Limitations & cautions

Abstract-only summary. The trial involved elective tumor craniotomy at five Indian centers, both groups also received locoregional analgesia, and the abstract does not provide longer-term outcome results in detail.
AI-summarized from the linked source. Review the original article before applying to practice.

Citations · exact source links

Journal of neurosurgical anesthesiology (PubMed). Opioid-Sparing Versus Opioid-Based Analgesia for Craniotomy: A Multicenter Randomized Controlled Trial.

Open original sourceFull brief

AI-summarized from the linked source. Review the original article before applying to practice.

How This Applies in Practice

Key takeaways

Practice implications

Limitations & cautions

Exact source links

More updates for this clinical area

IV pantoprazole did not improve vomiting or oral tolerance in pediatric gastroenteritis

Targeted vitamin D did not significantly reduce major cardiovascular events after MI

Dexmedetomidine did not improve early pain outcomes versus fentanyl for craniotomy